Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The safety and efficacy of L059 was evaluated in patients who completed "N165 Clinical Trial of L059". They received L059 at a daily dose from 1,000 mg to 3,000 mg in addition to their standard concomitant AEDs
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Levetiracetam | Experimental | Subjects received oral tablets of Levetiracetam. This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509). |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Levetiracetam | Drug |
|
|
| Measure | Description | Time Frame |
|---|---|---|
| Partial (Type I) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type I) seizures over the treatment period standardized to 1 week period. | From Baseline up to 54 months |
| Partial (Type IA) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period. | From Baseline up to 54 months |
| Partial (Type IB) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period. | From Baseline up to 54 months |
| Partial (Type IC) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period. | From Baseline up to 54 months |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | From Baseline up to 54 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| UCB Cares | 001 844 599 2273 (UCB) | Study Director |
Not provided
Not provided
| Label | URL |
|---|---|
| FDA Safety Alerts and Recalls | View source |
Not provided
Participant Flow refers to the Full Analysis Set (FAS). Of the 154 subjects who enrolled in the study, 151 subjects were included in the FAS population and 3 subjects were identified with major protocol deviations leading to exclusion from FAS.
The study started to enroll patients in September 2001 and concluded in January 2007.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | N165 Randomized Treatment PBO | Subjects received Placebo (PBO) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. |
| FG001 | N165 Randomized Treatment LEV | Subjects received Levetiracetam (LEV) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Full analysis Set (FAS)
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | N165 Randomized Treatment PBO (FAS) | Subjects received Placebo (PBO) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. |
| BG001 |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Partial (Type I) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type I) seizures over the treatment period standardized to 1 week period. | Full Analysis set included 151 subjects. Only subjects with valid data for partial (Type I) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Number of Seizures (Type I) per week | From Baseline up to 54 months |
|
Adverse events were collected from Visit 1 (Week 0) until 2 weeks after termination (up to 54 months).
Adverse events refer to the Full Analysis Set (FAS).
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | N165 Randomized Treatment PBO (FAS) | Subjects received Placebo (PBO) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. In the Placebo group the Serious Adverse Events (SAEs) Status epilepticus and Agitation occurred twice in 2 subjects. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Lymphadenitis | Blood and lymphatic system disorders | MedDRA9.0 | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Conjunctivitis | Eye disorders | MedDRA | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| UCB | Cares | +1844 599 | 2273 |
Not provided
| ID | Term |
|---|---|
| D004828 | Epilepsies, Partial |
| ID | Term |
|---|---|
| D004827 | Epilepsy |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000077287 | Levetiracetam |
| ID | Term |
|---|---|
| D000081 | Acetamides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000085 | Acetates |
| D000144 |
Not provided
Not provided
This study N01020 (NCT00160615) was designed as a single group assignment study and as follow-up study, open for patients from N165 (NCT00600509). The differentiation into placebo and Levetiracetam in the results reporting section is based on the treatment of the previously conducted study N165 (NCT00600509).
Not provided
Not provided
Not provided
Not provided
| Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit |
Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. |
| From Baseline up to 54 months |
| Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | From Baseline up to 54 months |
| Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | From Baseline up to 54 months |
| Lack of Efficacy |
|
| Patient decision |
|
| Investigator decision |
|
| AE agents had to be discontinued (exam.) |
|
| Switch to surgical treatment |
|
| Non-compliance was suspected |
|
| Poor compliance |
|
| N165 Randomized Treatment LEV (FAS) |
Subjects received Levetiracetam (LEV) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. |
| BG002 | Total Title |
| Years |
|
| Age, Customized | Number | Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| OG001 |
| N165 Randomized Treatment LEV |
Subjects received Levetiracetam (LEV) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. |
|
|
| Primary | Partial (Type IA) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IA) seizures over the treatment period standardized to 1 week period. | Subjects with Type IA seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IA) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Number of Seizures (Type IA) per week | From Baseline up to 54 months |
|
|
|
| Primary | Partial (Type IB) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IB) seizures over the treatment period standardized to 1 week period. | Subjects with Type IB seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IB) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Number of Seizures (Type IB) per week | From Baseline up to 54 months |
|
|
|
| Primary | Partial (Type IC) Seizure Frequency Per Week by Analysis Visit | Number of Partial (Type IC) seizures over the treatment period standardized to 1 week period. | Subjects with Type IC seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IC) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Number of Seizures (Type IC) per week | From Baseline up to 54 months |
|
|
|
| Secondary | Percentage Change From Baseline of Partial Onset Seizure Frequency (Type I Overall) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type I) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | Full Analysis set included 151 subjects. Only subjects with valid data for Partial (Type I seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Percent change | From Baseline up to 54 months |
|
|
|
| Secondary | Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IA) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type IA) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | Subjects with Type IA seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IA) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Percent change | From Baseline up to 54 months |
|
|
|
| Secondary | Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IB) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type IB) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | Subjects with Type IB seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IB) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Percent change | From Baseline up to 54 months |
|
|
|
| Secondary | Percentage Change From Baseline of Partial Onset Seizure Frequency (Subtype IC) Per Week by Analysis Visit | Percentage change from baseline of of Partial (Type IC) seizure frequency over the treatment period standardized to 1 week period. Negative values indicate improvement from Baseline. | Subjects with Type IC seizure count equal to zero during baseline and evaluation periods are excluded. Only subjects with valid data for partial (Type IC) seizure frequency per week at the respective visit are included in the analysis. Number of participants analyzed is given separately per visit. | Posted | Median | Inter-Quartile Range | Percent change | From Baseline up to 54 months |
|
|
|
| 0 |
| 50 |
| 12 |
| 50 |
| 48 |
| 50 |
| EG001 | N165 Randomized Treatment LEV (FAS) | Subjects received Levetiracetam (LEV) in study N165 [NCT00600509] and received LEV in this study: After starting with the 4 week-fixed 3000 mg/day, the daily doses of LEV were permitted to be adjusted by 500 or 1000 mg/day at a 4-week interval between 1000 mg/day and 3000 mg/day. | 1 | 101 | 22 | 101 | 99 | 101 |
| Abdominal pain lower | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Enterocolitis | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Gastric polyps | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Difficulty in walking | General disorders | MedDRA | Non-systematic Assessment |
|
| Drowning | General disorders | MedDRA | Non-systematic Assessment |
|
| Hyperthermia | General disorders | MedDRA | Non-systematic Assessment |
|
| Gallbladder polyp | Hepatobiliary disorders | MedDRA | Non-systematic Assessment |
|
| Appendicitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Pyelonephritis acute | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Ankle fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Femoral neck fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Fractured sacrum | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Head injury | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Joint dislocation | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Neck injury | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Polytraumatism | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Rib fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Skin laceration | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Rectal cancer | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Non-systematic Assessment |
|
| Convulsion | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Dyslalia | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Grand mal convulsion | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Status epilepticus | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Pregnancy | Pregnancy, puerperium and perinatal conditions | MedDRA | Non-systematic Assessment |
|
| Agitation | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Mental disorder | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Haemoptysis | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Pleurisy | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Abortion induced | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Mass excision | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Diplopia | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Abdominal pain | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Cheilitis | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Gastritis | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Gingivitis | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Stomatitis | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Toothache | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Chest pain | General disorders | MedDRA | Non-systematic Assessment |
|
| Malaise | General disorders | MedDRA | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA | Non-systematic Assessment |
|
| Seasonal allergy | Immune system disorders | MedDRA | Non-systematic Assessment |
|
| Dental caries | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Influenza | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Pharyngitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Arthropod sting | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Contusion | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Excoriation | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Joint sprain | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Mouth injury | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Open wound | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Skin laceration | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Thermal burn | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Blood alkaline phosphatase increased | Investigations | MedDRA | Non-systematic Assessment |
|
| Blood triglycerides increased | Investigations | MedDRA | Non-systematic Assessment |
|
| Blood urine present | Investigations | MedDRA | Non-systematic Assessment |
|
| Gamma-glutamyltransferase increased | Investigations | MedDRA | Non-systematic Assessment |
|
| Glucose urine present | Investigations | MedDRA | Non-systematic Assessment |
|
| Neutrophil count decreased | Investigations | MedDRA | Non-systematic Assessment |
|
| Protein urine present | Investigations | MedDRA | Non-systematic Assessment |
|
| Weight decreased | Investigations | MedDRA | Non-systematic Assessment |
|
| Weight increased | Investigations | MedDRA | Non-systematic Assessment |
|
| White blood cell count increased | Investigations | MedDRA | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Myalgia | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Pain in extremity | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Shoulder pain | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Convulsion | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Dizziness | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Epilepsy | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Hypoaesthesia | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Migraine | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Somnolence | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Tremor | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Pollakiuria | Renal and urinary disorders | MedDRA | Non-systematic Assessment |
|
| Dysmenorrhoea | Reproductive system and breast disorders | MedDRA | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Pharyngolaryngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Rhinitis allergic | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Upper respiratory tract inflammation | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Acne | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
Not provided
| Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D011760 | Pyrrolidinones |
| D011759 | Pyrrolidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|
| > 3 m - <= 6 m |
|
|
| > 6 m - <= 9 m |
|
|
| > 9 m - <= 12 m |
|
|
| > 12 m - <= 15 m |
|
|
| > 15 m - <= 18 m |
|
|
| > 18 m - <= 21 m |
|
|
| > 21 m - <= 24 m |
|
|
| > 24 m - <= 27 m |
|
|
| > 27 m - <= 30 m |
|
|
| > 30 m - <= 33 m |
|
|
| > 33 m - <= 36 m |
|
|
| > 36 m - <= 39 m |
|
|
| > 39 m - <= 42 m |
|
|
| > 42 m - <= 45 m |
|
|
| > 45 m - <= 48 m |
|
|
| > 48 m - <= 51 m |
|
|
| > 51 m - <= 54 m |
|
|
| > 54 m |
|
|